The aim of the present study was to investigate the nanoemulgel as transdermal delivery system for poorly water soluble drug, ketoprofen, in order to overcome the troubles associated with its oral delivery. Different nanoemulsion components (oil, surfactant, and cosurfactant) were selected on the basis of solubility and emulsification ability. Pseudoternary phase diagrams were constructed using titration method to figure out the concentration range of components. Carbomer 940 was added as gel matrix to convert nanoemulsion into nanoemulgel. Drug loaded nanoemulsions and nanoemulgels were characterized for particle size, TEM, viscosity, conductivity, spreadability, rheological behavior, and permeation studies using Wistar rat skin and stability studies. Transdermal permeation of ketoprofen from nanoemulgels was determined by using Franz diffusion cell. Nanoemulgel containing 6% oleic acid as oil, 35% Tween 80, and Transcutol P as surfactant cosurfactant mixture, 56.5% water, 2.5% drug, and 0.6% carbomer was concluded as optimized formulation (NG6). The ex vivo permeation profile of optimized formulation was compared with nanoemulsion and marketed formulation (Fastum). Nanoemulgel showed significantly higher () cumulative amount of drug permeated and flux along with lower lag time and skin retention than marketed formulation. Thus, the study substantiated that nanoemulgel formulation can be used as a feasible alternative to conventional formulations of ketoprofen with advanced permeation characteristics for transdermal application. 1. Introduction Nanoemulsion is a promising tool for transdermal drug delivery and is defined as a dispersion consisting of oil, surfactant, cosurfactant, and aqueous phase, which is a single optically isotropic and thermodynamically stable liquid solution with a droplet diameter usually in range of 10–200？nm [1]. The ascendancies associated with transdermal use of nanoemulsion are as enhanced drug solubility, good thermodynamic stability, and enhancing effect on transdermal ability [2]. The aptness of nanoemulsion to increase the concentration gradient and thermodynamic activity towards skin along with permeation enhancement activity of its components makes the system expedient for transdermal delivery. But the low viscosity of nanoemulsion constrains its application in transdermal delivery due to cumbersome use. Biocompatible gels having weak interaction with surfactants have already been explored to modify the rheological behavior of nanoemulsion [3]. Variant gel matrices such as carbomer 940, xanthan gum, and carrageenan
References
[1]
B. Singh, R. Singh, S. Bandyopadhyay, R. Kapil, and B. Garg, “Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol,” Colloids and Surfaces B: Biointerfaces, vol. 101, pp. 465–474, 2013.
[2]
J.-H. Zhao, L. Ji, H. Wang, et al., “Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo,” International Journal of Nanomedicine, vol. 6, pp. 1611–1619, 2011.
[3]
K. W. Ambade, S. L. Jadhav, M. N. Gambhire, S. D. Kurmi, V. J. Kadam, and K. R. Jadhav, “Formulation and evaluation of flurbiprofen microemulsion,” Current Drug Delivery, vol. 5, no. 1, pp. 32–41, 2008.
[4]
E. Yilmaz and H.-H. Borchert, “Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema—an in vivo study,” International Journal of Pharmaceutics, vol. 307, no. 2, pp. 232–238, 2006.
[5]
H. Adachi, F. Ioppolo, M. Paoloni, and V. Santilli, “Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 7, pp. 823–830, 2011.
[6]
F. Glówka, M. Kara？niewicz-Lada, E. Grze？kowiak, D. Rogozinska, and W. Romanowski, “Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 36, no. 3, pp. 167–173, 2011.
[7]
N. Shinkai, K. Korenaga, Y. Okumura, H. Mizu, and H. Yamauchi, “Microdialysis assessment of percutaneous penetration of ketoprofen after transdermal administration to hairless rats and domestic pigs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 3, pp. 415–421, 2011.
[8]
P. K. Shetty, N. A. Suthar, J. Menon et al., “Transdermal delivery of lercanidipine hydrochloride: effect of chemical enhancers and ultrasound,” Current Drug Delivery, vol. 10, no. 4, pp. 427–434, 2013.
[9]
S. Baboota, F. Shakeel, A. Ahuja, J. Ali, and S. Shafiq, “Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib,” Acta Pharmaceutica, vol. 57, no. 3, pp. 315–332, 2007.
[10]
D. Mou, H. Chen, D. Du et al., “Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs,” International Journal of Pharmaceutics, vol. 353, no. 1-2, pp. 270–276, 2008.
[11]
H. Chen, X. Chang, D. Du, J. Li, H. Xu, and X. Yang, “Microemulsion-based hydrogel formulation of ibuprofen for topical delivery,” International Journal of Pharmaceutics, vol. 315, no. 1-2, pp. 52–58, 2006.
[12]
W. Zhu, C. Guo, A. Yu, Y. Gao, F. Cao, and G. Zhai, “Microemulsion-based hydrogel formulation of penciclovir for topical delivery,” International Journal of Pharmaceutics, vol. 378, no. 1-2, pp. 152–158, 2009.
[13]
G. Aggarwal, S. Dhawan, and S. L. Harikumar, “Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine,” Pharmaceutical Development and Technology, vol. 18, no. 4, pp. 916–925, 2013.
[14]
V. Ntimenou, A. Fahr, and S. G. Antimisiaris, “Elastic vesicles for transdermal drug delivery of hydrophilic drugs: a comparison of important physicochemical characteristics of different vesicle types,” Journal of Biomedical Nanotechnology, vol. 8, no. 4, pp. 613–623, 2012.
[15]
G. N. El-Hadidy, H. K. Ibrahim, M. I. Mohamed, and M. F. El-Milligi, “Microemulsions as vehicles for topical administration of voriconazole: formulation and in vitro evaluation,” Drug Development and Industrial Pharmacy, vol. 38, no. 1, pp. 64–72, 2012.
[16]
W. Liu, R. Tian, W. Hu et al., “Preparation and evaluation of self-microemulsifying drug delivery system of baicalein,” Fitoterapia, vol. 83, no. 8, pp. 1532–1539, 2012.
[17]
S. Mura, M. Manconi, D. Valenti, C. Sinico, A. O. Vila, and A. M. Fadda, “Transcutol containing vesicles for topical delivery of minoxidil,” Journal of Drug Targeting, vol. 19, no. 3, pp. 189–196, 2011.
[18]
T. Ngawhirunpat, N. Worachun, P. Opanasopit, T. Rojanarata, and S. Panomsuk, “Cremophor RH40-PEG 400 microemulsions as transdermal drug delivery carrier for ketoprofen,” Pharmaceutical Development and Technology, vol. 18, no. 4, pp. 798–803, 2013.
[19]
H. Chen, D. Mou, D. Du et al., “Hydrogel-thickened microemulsion for topical administration of drug molecule at an extremely low concentration,” International Journal of Pharmaceutics, vol. 341, no. 1-2, pp. 78–84, 2007.
[20]
R. Aboofazeli, D. J. Barlow, and M. J. Lawrence, “Particle size analysis of concentrated phospholipid microemulsions: I. Total intensity light scattering,” AAPS PharmSci, vol. 2, no. 2, pp. 1–13, 2000.
[21]
B. Biruss, H. K？hlig, and C. Valenta, “Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones,” International Journal of Pharmaceutics, vol. 328, no. 2, pp. 142–151, 2007.
[22]
J. Jiao and D. J. Burgess, “Rheology and stability of water-in-oil-in-water multiple emulsions containing span 83 and tween 80,” AAPS PharmSci, vol. 5, no. 1, pp. 62–73, 2003.
[23]
D. Kaushik, P. Batheja, B. Kilfoyle, V. Rai, and B. Michniak-Kohn, “Percutaneous permeation modifiers: enhancement versus retardation,” Expert Opinion on Drug Delivery, vol. 5, no. 5, pp. 517–529, 2008.
[24]
K. Shinoda and B. Lindman, “Organized surfactant systems: microemulsions,” Langmuir, vol. 3, no. 2, pp. 135–149, 1987.
[25]
A. Azeem, M. Rizwan, F. J. Ahmad et al., “Nanoemulsion components screening and selection: a technical note,” AAPS PharmSciTech, vol. 10, no. 1, pp. 69–76, 2009.
[26]
C. H. Lee, V. Moturi, and Y. Lee, “Thixotropic property in pharmaceutical formulations,” Journal of Controlled Release, vol. 136, no. 2, pp. 88–98, 2009.
